About

David A. Lipson, M.D., is an Adjunct Associate Professor of Medicine in the Department of Medicine at the University of Pennsylvania's Perelman School of Medicine. His clinical expertise focuses on advanced lung diseases, including COPD, emphysema, adult cystic fibrosis, bronchiectasis, and lung transplantation. He is involved in medical evaluation for lung volume reduction surgery for emphysema and specializes in the management of patients with severe pulmonary conditions. His research expertise encompasses advanced imaging technologies such as MRI, hyperpolarized noble gas imaging, and the study of ventilation and perfusion relationships in the lungs. Lipson has contributed to the understanding of obliterative bronchiolitis and has engaged in clinical research related to pulmonary function and imaging. His work includes the development and application of functional lung imaging techniques, with a focus on radiologic considerations in cystic fibrosis and lung transplantation. His scholarly contributions include numerous publications on these topics, emphasizing the integration of imaging technology with clinical practice to improve diagnosis and treatment of lung diseases.

Research topics

• Medicine
• Internal medicine
• Physical therapy
• Intensive care medicine
• Anesthesia

Selected publications

• Effects of seasonality and treatment on COPD clinical outcomes: IMPACT<i>post hoc</i>analysis

  ERJ Open Research · 2024-09-27

  articleOpen access

  <title>Extract</title> COPD exacerbation rates vary during the year, with higher rates and a greater proportion of patients experiencing exacerbations in the winter months [1, 2]. These seasonal effects are driven by a wide range of factors, including host physiology, environmental factors and differing rates of pathogen exposure [3].

  PublisherDOI

• The Effect of Patient Sex on Treatment Outcomes in COPD: A Post Hoc Analysis of the IMPACT Trial

  Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2024-01-01

  articleOpen access

  Introduction: Lung physiology and chronic obstructive pulmonary disease (COPD) pathophysiology differ between sexes. This post hoc analysis investigated the InforMing the Pathway of COPD Treatment (IMPACT) trial outcomes by patient sex. Methods: ) and St George's Respiratory Questionnaire (SGRQ) score, and safety were assessed. Results: =0.013) with FF/UMEC/VI versus UMEC/VI. Conclusion: More females with COPD reported exacerbations in the prior year at screening, as well as during the study, versus males, across all treatments. FF/UMEC/VI improved exacerbation rates versus UMEC/VI in females with eosinophil counts <150 cells/µL or <2 exacerbations in the prior year, suggesting inhaled corticosteroids may play an important role in exacerbation reduction for females in this patient population. Clinical Trial Registration: GSK (CTT116855/NCT021645B).

  PublisherOA PDFDOI

• Indicateurs de risque de complications cardiopulmonaires détectés grâce à la réalisation d’un ECG chez des patients atteints de bronchopneumopathie chronique obstructive : analyse post-hoc de l’étude IMPACT

  Revue des Maladies Respiratoires Actualités · 2024-01-01

  article
  PublisherDOI

• ECG-based risk factors for adverse cardiopulmonary events and treatment outcomes in COPD

  European Respiratory Journal · 2024-10-28 · 9 citations

  articleOpen access

  Background COPD has high mortality, compounded by comorbid cardiovascular disease. We investigated two ECG markers, Cardiac Infarction Injury Score (CIIS) and P pulmonale, as prognostic tools for adverse cardiopulmonary events in COPD. Methods This was a p ost hoc analysis of the IMPACT trial. Outcomes included odds (odds ratio, 95% confidence intervals) of adverse cardiopulmonary events stratified by CIIS threshold (&lt;20 versus ≥20) and P pulmonale (baseline). Events included all-cause death, hospitalisation or death, cardiovascular adverse event of special interest, severe COPD exacerbations, and moderate/severe COPD exacerbations. We also assessed the effects of fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol or umeclidinium/vilanterol based on CIIS and P pulmonale. Results We included 9448 patients. Patients with CIIS ≥20 ( versus CIIS &lt;20) had greater odds of all-cause death (OR 1.73, 95% CI 1.27–2.37, p&lt;0.001), hospitalisation or death (OR 1.33, 95% CI 1.17–1.50, p&lt;0.001), cardiovascular adverse event of special interest (OR 1.27, 95% CI 1.08–1.48, p&lt;0.005), severe COPD exacerbations (OR 1.41, 95% CI 1.21–1.64, p&lt;0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.13–1.40, p&lt;0.001). Patients with P pulmonale ( versus without) had greater odds of all-cause death (OR 2.25, 95% CI 1.54–3.29, p&lt;0.001), hospitalisation or death (OR 1.51, 95% CI 1.28–1.79, p&lt;0.001), severe COPD exacerbations (OR 2.00, 95% CI 1.65–2.41, p&lt;0.001) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.08–1.46, p&lt;0.001). A combined model demonstrated that patients with CIIS ≥20 and P pulmonale had increased risk of all-cause death (OR 3.38, 95% CI 1.23–9.30, p=0.019), hospitalisation or death (OR 1.61, 95% CI 1.14–2.22, p=0.004) and rate of severe COPD exacerbations (OR 1.89, 95% CI 1.22–2.91, p=0.004) and moderate/severe COPD exacerbations (OR 1.25, 95% CI 1.00–1.56, p=0.046). The risk of all-cause death and cardiovascular adverse events of special interest was reduced with fluticasone furoate/umeclidinium/vilanterol versus umeclidinium/vilanterol in patients with CIIS ≥20, but not CIIS &lt;20. Conclusions These findings suggest the potential clinical relevance of CIIS and P pulmonale as risk indicators for adverse cardiopulmonary events in COPD.

  PublisherOA PDFDOI

• How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?

  Chronic Respiratory Disease · 2023-10-06 · 2 citations

  reviewOpen access

  This review addresses outstanding questions regarding initial pharmacological management of chronic obstructive pulmonary disease (COPD). Optimizing initial treatment improves clinical outcomes in symptomatic patients, including those with low exacerbation risk. Long-acting muscarinic antagonist/long-acting β 2 -agonist (LAMA/LABA) dual therapy improves lung function versus LAMA or LABA monotherapy, although other treatment benefits have been less consistently observed. The benefits of dual bronchodilation in symptomatic patients with COPD at low exacerbation risk, and its duration of efficacy and cost effectiveness in this population, are not yet fully established. Questions remain on the impact of baseline symptom severity, prior treatment, degree of reversibility to bronchodilators, and smoking status on responses to dual bronchodilator treatment. Using evidence from EMAX (NCT03034915), a 6-month trial comparing the LAMA/LABA combination umeclidinium/vilanterol with umeclidinium and salmeterol monotherapy in symptomatic patients with COPD at low exacerbation risk who were inhaled corticosteroid-naïve, we describe how these findings can be applied in primary care.

  PublisherDOI

• Late Breaking Abstract - ECG-derived risk factors for adverse cardiopulmonary outcomes in COPD patients: IMPACT post hoc analysis

  2023-09-09 · 1 citations

  article

  <b>Introduction:</b> Cardiac Infarction Injury Score (CIIS) and right heart dysfunction (P pulmonale) may aid as ECG prognostic tools to identify COPD patients benefiting from triple therapy. <b>Aim:</b> Assess association of CIIS and P pulmonale with adverse outcomes and treatment response. <b>Methods:</b> IMPACT post hoc analysis assessed risk of death, hospitalization, CVAESI, or exacerbation by CIIS (CIIS≥20 vs &lt;20) and P pulmonale (yes vs no), and by treatment (FF/UMEC/VI vs FF/VI and UMEC/VI), using t-test, Fisher’s exact test, Cox proportional hazards models or generalized linear modeling as appropriate. <b>Results:</b> Patients with CIIS≥20 had significantly greater risk of worse clinical outcomes vs CIIS&lt;20 (<b>Figure 1</b>). Patients with P pulmonale had similar results, except for CVAESI. In those with CIIS≥20 FF/UMEC/VI was associated with lower risk of CVAESI vs UMEC/VI; in those with P pulmonale FF/UMEC/VI was associated with lower risk of hospitalization or death vs FF/VI and UMEC/VI (<b>Figure 2</b>). <b>Conclusion:</b> COPD patients with CIIS≥20 or P pulmonale have increased risk of adverse outcomes and may benefit most from triple therapy. <b>Funding:</b> GSK: 116855/NCT02164513

  PublisherDOI

• Any Decrease in Lung Function is Associated With Worse Clinical Outcomes: Post Hoc Analysis of the IMPACT Interventional Trial

  Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2023-12-11 · 2 citations

  articleOpen access

  This article does not contain an abstract.

  PublisherOA PDFDOI

• Best Practice Management of Patients With Chronic Obstructive Pulmonary Disease: A Case-Based Review

  The Journal for Nurse Practitioners · 2022-05-16

  reviewOpen access
  PublisherOA PDFDOI

• Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial

  International Journal of COPD · 2022-07-01 · 3 citations

  articleOpen access

  Objectives: In the IMPACT trial (NCT02164513), triple therapy with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) showed clinical benefit compared with dual therapy with either FF/VI or UMEC/VI in the treatment of chronic obstructive pulmonary disease (COPD). We used data from IMPACT to determine whether this translated into differences in COPD-related healthcare resource utilization (HRU) costs in a United Kingdom (UK) setting. Methods: In a within-trial analysis, individual patient data from the IMPACT intention-to-treat (ITT) population were analyzed to estimate rates of COPD-related HRU with FF/UMEC/VI, FF/VI, or UMEC/VI. A Bayesian approach was applied to address issues typically encountered with this kind of data, namely data missing due to early study withdrawal, subjects with zero reported HRU, and skewness. Rates of HRU were estimated under alternate assumptions of data being missing at random (MAR) or missing not at random (MNAR). UK-specific unit costs were then applied to estimated HRU rates to calculate treatment-specific costs. Results: Under each MNAR scenario, per patient per year (PPPY) rates of COPD-related HRU were lowest amongst those patients who received treatment with FF/UMEC/VI compared with those receiving either FF/VI or UMEC/VI. Although absolute HRU rates and costs were typically higher for all treatment groups under MNAR scenarios versus MAR, final economic conclusions were robust to patient withdrawals. Conclusions: PPPY rates were typically lower with FF/UMEC/VI versus FF/VI or UMEC/VI.

  PublisherOA PDFDOI

• Correction to: Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study

  Advances in Therapy · 2022-01-21

  erratumOpen accessSenior author
  PublisherOA PDFDOI

Recent grants

• NIH Grant K23HL004486

  NIH · $651k · 2006

Frequent coauthors

• Fernando J. Martínez

  Cornell University

  191 shared

• Robert A. Wise

  Pulmonary and Critical Care Associates

  162 shared

• Dave Singh

  Manchester University NHS Foundation Trust

  125 shared

• Peter Lange

  Gentofte Hospital

  92 shared

• Mark T. Dransfield

  University of Alabama at Birmingham

  89 shared

• Robert M. Kotloff

  Hospital of the University of Pennsylvania

  88 shared

• Gerard J. Criner

  86 shared

• François Maltais

  82 shared

Labs

• David A. Lipson LabPI